Drug-eluting bioresorbable stents for various applications

Annual Review of Biomedical Engineering

Volumn 8, Issue , 2006, Pages 153-180

  Zilberman, Meital ^a   Eberhart, Robert C ^b,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bioresorbable polymer; Drug delivery; Protein delivery; Stent

Indexed keywords

BIOLOGICAL ORGANS; BIOMEDICAL ENGINEERING; CELLS; DISEASE CONTROL; DRUG PRODUCTS; TISSUE;

BIORESORBABLE POLYMERS; DRUG DELIVERY; PROTEIN DELIVERY; STENTS;

BIOMEDICAL EQUIPMENT;

DEXAMETHASONE; NITINOL; PACLITAXEL; POLYCAPROLACTONE; POLYDIOXANONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; RAPAMYCIN; RESOMER; SIMVASTATIN; TRANILAST;

ARTERY DISSECTION; ARTERY INTIMA PROLIFERATION; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; BRONCHUS OBSTRUCTION; CORONARY STENT; DEVICE; DRUG ELUTING STENT; DRUG RELEASE; ESOPHAGUS STRICTURE; FILM; GASTROINTESTINAL OBSTRUCTION; GLASS TRANSITION TEMPERATURE; PROSTATE HYPERTROPHY; RESTENOSIS; REVIEW; SCANNING ELECTRON MICROSCOPY; TENSILE STRENGTH; TRACHEA OBSTRUCTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ABSORBABLE IMPLANTS; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; DRUG CARRIERS; DRUG IMPLANTS; EQUIPMENT DESIGN; HUMANS; STENTS;

EID: 33748167399     PISSN: 15239829     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.bioeng.8.013106.151418     Document Type: Review

References (103)

1. Fishman DL, Leon MB, Baim DS, Schatz RA, Savage MP, et al. 1994. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 331:496-501
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, et al. 1994. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 331:489-95
3. Stefanidis IK, Tolis VA, Sionis DG, Michalis LK. 2002. Development in intracoronary stents. Hell. J. Cardiol. 43:63-67
4. Carter AJ, Scott D, Rahdert D, Bailey L, de Vries J, et al. 1999. Stent design favorably influences the vascular response in normal porcine coronary arteries. J. Invasive Cardiol. 11:127-34
5. Dumonceau JM, Deviere J. 1999. Self-expandable metal stents. Baillieres Best Pract. Res. Clin. 13:109-30
6. Ozaki Y, Violaris AG, Serruys PW. 1996. New stent technologies. Prog. Cardiovasc. Dis. 39:129-40
7. Vioralis AG, Ozaki Y, Serruys PW. 1997. Endovascular stents: a 'break through technology', future challenges. Int. J. Cardiac Imaging 13:3-13
8. Nicholson T. 1999. Stents: an overview. Hosp. Med. 60:571-73
9. Cleveland TJ, Gaines P. 1999. Stenting in peripheral vascular disease. Hosp. Med. 60:630-32
10. Barras CDJ, Myers KA. 2000. Nitinol-its use in vascular surgery and other applications. Eur. J. Vasc. Endovasc. Surg. 19:564-69
11. Ross R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 331:489-95
12. Tanaka K, Honda M, Kuramochi T. 1994. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis 107:179-85
13. Honda Y, Grube E, de la Fuente LM, Yock PG, Stertzer SH, Fitzgerald PJ. 2001. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 104:380-83
14. Liistro F, Stankovic G, Di Mario C, Takagi T, Chieffo A, et al. 2002. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 105:1883-86
15. Degerteldn M, Serruys PW, Foley DP, Tanabe K, Regar E, et al. 2002. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) cinical, angiographic, and intravascular ultrasound follow-up. Circulation 106:1610-13
16. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, et al. 2001. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angioplasty and three-dimensional intravascular ultrasound study. Circle 103:192-95
17. Sollot SJ, Cheng L, Pauly RR, Jenkings GM, Monticone RE, et al. 1995. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J. Clin. Interv. 95:1869-76
18. Am. Soc. Health Syst. Pharm. 1989. AHFS Drug Information, pp.1075-86. Bethseda, MD: Am. Soc. Health Syst. Pharm.
19. Rowinsky EK, Donehower RC. 1995. Drug therapy: paclitaxel (Taxol). N. Engl. J. Med. 332:1002-14
20. Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, et al. 1998. Intraluminal delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J. Am. Coll. Cardiol. 32:780-86
21. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, et al. 2000. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36:2325-32
22. Suh H, Jeong B, Rathi R, Kim SW. 1998. Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/ glycolide) nanospheres. J. Biomed. Mater. Res. 42:331-38
23. Alexis F, Venkatraman SS, Rath SK, Boey F. 2004. In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J. Control. Release 98:67-74
24. Burton PBJ, Yacoub MH, Barton PJR. 1998. Rapamycin (sirolimus) inhibits heart cell growth in vitro. Pediatr. Cardiol. 19:468-70
25. Kahan BD, Camardo JS. 2001. Rapamycin: clinical results and future opportunities. Transplantation. 72:1181-93
26. Morice MC, Serruys PW, Sousa JE, Perin M, Colombo A, et al. 2002. RAVEL study group, a randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346:1773-80
27. Regar E, Laarman G, Blanchard D, Eltchaninoff H, Sousa JE, et al. 2002. Sirolimus. inhibits restenosis irrespective of the vessel size: a subanalysis of the multicenter RAVEL trial. J. Am. Coll. Cardiol. 39:58A
28. Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ, et al. 2003. Sirolimus-eluting stent for treatment of complex in-stent restenosis, the first clinical experiences. J. Am. Coll. Cardiol. 41:184-89
29. Regar E, Serruys PW, Bode C, Holubarsch C, Guermonprez JL, et al. 2002. Angiographic findings of the multicenter randomized study with the sirolimus-eluting Bx velocity balloon expandable stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106:1949-56
30. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al. 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349:1315-23
31. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, et al. 2003. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107:38-42
32. Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, et al. 2004. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analysis: data from the randomized TAXUS-II trial. Circulation 109:196-200
33. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, et al. 2003. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in slow-release polymer formulation. Circulation 107:559-64
34. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al. 2004. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350:221-31
35. Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, et al. 2003. Biodegradable stents as a platform to drug loading. Int. J. Cardiovasc. Interv. 5:13-16
36. Talja M, Valimaa T, Tammela T, Petas A, Tormala P. 1997. Bioabsorbable and biodegradable stents in urology. J. Endourol. 11:391-97
37. Kapoor R, Liatsikos EN, Badlani G. 2000. Endoprostatic stents for management of benign prostatic hyperplasia. Curr. Opin. Urol. 10:19-22
38. Kletscher BA, Oesterling JE. 1995. Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia. Urol. Clin. North Am. 22:423-30
39. de la Rosette JJMC, Beerlage HP, Debruyne FMJ. 1997. Role of temporary stents in alternative treatment of benign prostatic hyperplasia. J. Endourol. 11:467-72
40. Kemppainen E, Talija M, Riihela M, Pohjonen T, Tormala P, Alfthan O. 1993. A bioresorbable urethral stent. An experimental study. Urol. Res. 21:235-38
41. Petas A, Talja M, Tammela T, Taari K, Lehtoranta K, et al. 1997. A randomized study to compare biodegradable self-reinforced polyglycolic acid spiral stents to suprapubic and indwelling catheters after visual laser ablation of the prostate. J. Urol. 157:173-76
42. Petas A, Isotalo T, Talja M, Tammela TLJ, Valimaa T, Tormala P. 2000. A randomised study to evaluate the efficacy of a biodegradable stent in the prevention of postoperative urinary retention after interstitial laser coagulation of the prostate. Scand. J. Urol. Nephrol. 34:262-66
43. Petas A, Karkkainen P, Talja M, Taari K, Laato M, et al. 1997. Effects of biodegradable self-reinforced polyglycolic acid, poly-DL-lactic acid and stainless-steel spiral stents on uroepithelium after Nd:YAG laser irradiation of the canine prostate. Br. J. Urol. 80:903-7
44. Lumiaho J, Heino A, Pietilainen T, Ala-Opas M, Talja M, et al. 2000. The morphological, in situ effects of a self-reinforced bioabsorbable polylactide (SR-PLA 96) ureteric stent; an experimental study. J. Urol. 164:1360-63
45. Lumiaho J, Heino A, Tunninen V, Ala-Opas M, Talja M, et al. 1999. New bioabsorbable polylactide ureteral stent in the treatment of ureteral lesions: an experimental study. J. Endourol. 13:107-12
46. Rafanan AL, Mehta AC. 2000. Stenting of the tracheobronchial tree. Radiol. Clin. North Am. 38:395-408
47. Robey TC, Eiselt PM, Murphy HS, Mooney DJ, Weatherly RA. 2000. Biodegradable external tracheal stents and their use in a rabbit tracheal reconstruction model. Laryngoscope 110:1936-42
48. Lochbihler H, Hoelzi J, Dietz H. 1997. Tissue compatibility and biodegradation of new absorbable stents for tracheal stabilization: an experimental study. J. Pediatr. Surg. 32:717-20
49. Filler RM, Forte V, Farga JC, Matute J. 1995. The use of expandable metallic airway stents for tracheobronchial obstruction in children. J. Pediatr. Surg. 30:1050-55
50. Furman RH, Backer CL, Dunham M, Donaldson J, Mavroudis C, Holinger LD. 1999. The use of balloon-expandable metallic stents in the treatment of pediatric tracheomalacia and bronchomalacia. Arch. Otolaryngol. Head Neck Surg. 125:203-7
51. Lamber R. 2000. Treatment of esophagogastric tumors. Endoscopy 32:322-31
52. Morgan R, Adam A. 2001. Use of metallic stents and balloons in the esophagus and gastrointestinal tract. J. Vasc. Interv. Radiol. 12:283-97
53. Nicholson T. 2000. Other uses of nonvascular stents. Hosp. Med. 61:97-102
54. Kimura T, Yokoi H, Nakagawa Y. 1996. Three-year follow-up after implantation of metallic coronary artery stents. N. Engl. J. Med. 334:561-66
55. Eberhart RC, Su SH, Kytai TN, Zilberman M, Liping T, et al. 2003. Bioresorbable polymeric stents: current status and future promise. J. Biomater. Sci. Polym. Ed. 14(4):299-312
56. Nguyen K, Su SH, Zilberman M, Bohluli P, Frenkel P, et al. 2004. Biomaterials and stent technology. In Tissue Engineering and Novel Delivery Systems, ed. M Yaszemski, D Trantolo, KU Lewandrowski, V Hasirci, D Altobelli, D Wise, 5:107-30. New York: Marcel Dekker
57. Kohn J, Langer R. 2000. Bioresorbable and bioerodible materials. In Biomaterials Science-An Introduction to Materials in Medicine, ed. BD Ratner, AS Hoffman, FJ Schoen, JE Lemons, pp 64-73. New York: Academic
58. Leenslag JW, Pennings AJ, Bos RRM, Rosema FR, Boering G. 1987. Resorbable materials of poly(L-lactic acid). VI. Plates and screws for internal fracture fixation. Biomaterials 8:70-73
59. Bergsma EJ, Rozema FR, Bos RRM, de Bruijn WC. 1993. Foreign body reactions to resorbable poly(L-lactide) bone plates and screws used for the fixation of unstable zygomatic fractures. J. Oral Maxillofac. Surg. 51:666-70
60. Bergsma EJ, de Bruijn WC, Rozema FR, Bos RRM, Boering G. 1995. Late degradation tissue response to poly(L-lactide) bone plates and screws. Biomaterials 16:25-31
61. Agrawal CM, Haas KF, Leopold DA, Clark H. 1992. Evaluation of poly(L-lactic acid) as a material for intravascular polymeric stents. Biomaterials 13:176-82
62. Pachence JM, Kohn J. 2000. Bioresorbable polymers for tissue engineering. In Principles of Tissue Engineering, ed. RP Lanza, R Langer, WL Chick, pp. 267-70. San Diego: Academic
63. Lewis DH. 1990. Controlled release of bioactive agents from lactide/glycolide polymers. In Biodegradable Polymers as Drug Delivery Systems, ed. M Chasin, R Langer, pp. 1-41. New York: Marcel Dekker
64. Leelarusamee N, Howard SA, Malango CJ, Ma JK. 1998. A method for the preparation of polylactic acid microencapsules of controlled particle size and drug loading. J. Microencapsul. 5:147-57
65. Gorman S, Tunney M. 1997. Assessment of encrustation behavior on urinary tract biomaterials. J. Biomater. Appl. 12:136-66
66. Petas A, Vuopio-Varkila J, Siitonen A, Valimaa T, Talja M, Taari K. 1998. Bacterial adherence to self-reinforced polylactic acid 96 urological spiral stents in vitro. Biomaterials 19:677-81
67. Multanen M, Talja M, Hallanvuo S, Siitonen A, Valimaa T, et al. 2000. Bacterial adherence to ofloxacin-blended polylactone-coated self-reinforced L-lactic acid polymer urological stents. BJU Int. 86:966-69
68. Zidar J, Lincoff A, Stack R. 1999. Biodegradable stents. In Textbook of Interventional Cardiology, ed. EJ Topol, pp. 787-802. Philadelphia: WB Saunders. 3rd ed.
69. Stack RS, Califf RM, Phillips HR, Pryor DB, Quigley PJ, et al. 1988. Interventional cardiac catheterization at Duke Medical Center: new interventional technology. Am. J. Cardiol. 2:3F-24
70. Gao R, Shi R, Qiao S, Song L, Li Y. 1996. A novel polymeric local heparin delivery stent: initial experimental study. J. Am. Coll. Cardiol. 27:85A
71. Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, et al. 1998. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J. Am. Coll. Cardiol. 32:780-86
72. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, et al. 2000. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation 102:399-404
73. Zilberman M, Eberhart R, Schwade N. 2002. In vitro study of drug loaded bioresorbable films and support structures. J. Biomater. Sci. Polym. Ed. 13:1221-40
74. Nuutinen JP, Valimaa T, Clerc C, Tormala P. 2002. Mechanical properties and in vitro degragation of bioresorbable knitted stents. J. Biomater. Sci. Polym. Ed. 13(12):1313-23
75. Saito Y, Minami K, Kobayashi M, Nakao Y, Omiya H, et al. 2002. New tubular bioabsorbable knitted airway stent: biocompatibility and mechanical strength. J. Thorac. Cardiovasc. Surg. 123:161-67
76. Tamai H, Igaki K, Tsuji T, Miyata K, Higo T, et al. 1999. A biodegradable poly-L-lactic acid coronary stent in porcine coronary artery. J. Interv. Cardiol. 12:443-49
77. Schwartz RS, Huber KC, Murphy JG. 1992. Restenosis and the proportional response to coronary artery injury: results in a porcine model. J. Am. Cardiol. 19:267-74
78. Karas SP, Gravanis MB, Santoian EC. 1992. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J. Am. Coll. Cardiol. 20:467-74
79. Tsuji T, Tamai H, Kyo E. 1998. The effect of PLLA stent design on neointimal hyperplasia. J. Cardiol. 32:235A
80. Tamai H, Igaki K, Tsuji T. 1999. A biodegradable poly-L-lactic acid coronary stent in procine coronary artery. J. Interv. Cardiol. 12:443-50
81. Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, et al. 2001. Biodegradable polymeric stents. Curr. Interven. Cardiol. Rep. 3:10-17
82. Miyazawa K, Kikuchi S, Fukuyama J. 1995. Inhibition of PDGF and TGF-beta 1- induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells. Atherosclerosis 118:213-21
83. Fukuyama J, Ichikawa K, Hamano S. 1996. Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed in a high cholesterol diet. Eur. J. Pharmacol. 318:327-32
84. Miyazawa N, Umemura K, Kondo K. 1997. Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat. J. Cardiovasc. Pharmacol. 30:157-62
85. Ishiwata S, Verheye S, Robinson KA. 2000. Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation. J. Am. Coll. Cardiol. 35:1331-37
86. Uurto I, Mikkonen J, Parkkinen J, Keski-Nisula L, Nevalainen T, et al. 2005. Drug-eluting bioresorbable poly-D/L-lactic acid vascular stents: an experimental pilot study. J. Endovasc. Ther. 12:371-79
87. Zilberman M, Schwade ND, Eberhart RC. 2004. Protein-loaded bioresorbable fibers and expandable stents: mechanical properties and protein release. J. Biomed. Mater. Res. Part B Appl. Biomater. 69B:1-10
88. Su S, Chao RY, Landau CL, Nelson KD, Timmons RB, et al. 2003. Expandable bioresorbable endovascular stent. I. Fabrication and properties. Ann. Biomed. Eng. 31:667-77
89. Zilberman M. 2006. Novel composite fiber structures to provide drug delivery for medical implants and tissue regeneration application. Acta Biomater. Submitted
90. Levy Y, Zilberman M. 2006. Nove bioresorbable fiber structures loaded with proteins for tissue regeneration applications: microstructure and protein release. J. Biomed. Mater. Res. (Pt. A). In press
91. Zilberman M, Shraga I. 2006. Microsphere-based bioresorbable structures loaded with Proteins for tissue regeneration applications. J. Biomed. Mater. Res. (Pt. A). In press
92. Kraitzer A. 2006. Paclitaxel loaded core/shell fiber structures for stein applications. MSc thesis. Tel Aviv Univ.
93. Woods TC, Marks AR. 2004. Drug-Eluting Stents. Annu. Rev. Med. 55:169-78
94. Sousa JE, Serruys PW, Costa MA. 2003. New frontiers in cardiology: drug-eluting stents: part II. Circulation 107:2383-89
95. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, et al. 2000. Neointimal thickening after stent delivery of Paclitaxel: Change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36(7):2325-32
96. Duda SH, Poerner TC, Wiesinger B, Rundback JH, Tepe G, et al. 2003. Drug-eluting stents: potential applications for peripheral arterial occlusive disease. J. Vascul. Interven. Radiol. 14:291-301
97. Zilberman M, Nelson KD, Eberhart R. 2005. Mechanical properties and in-vitro degradation of bioresorbable fibers and expandable fiber-based stents. J. Biomed. Mater. Res. Part B Appl. Biomater. 74B:792-99
98. Greisler HP, Ellinger J, Schwarcz TH, Golan J, Raymond RM, Kim DU. 1987. Arterial regeneration over polydioxanone prostheses in the rabbit. Arch. Surg., Chicago. 122:715-21
99. Makela EA, Vainionpaa S, Vihtonen K, Mero M, Helevirta P, et al. 1989. The effect of a penetrating biodegradable implant on the growth plate: an experimental study on growing rabbits with special reference to polydioxanone. Clin. Orthop. 241:300-8
100. Ye YW, Landau C, Willard JE, Rajasubramanian G, Moskowitz A, et al. 1998. Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall. Ann. Biomed. Eng. 26:398-408
101. Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, et al. 2004. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur. Heart. J. 25:1330-40
102. Zilberman M, Schwade N, Meideil R, Eberhart R. 2001. Structured drug loaded bioresorbable films for support structures. J. Biomater. Sci. Polym. Ed. 12:875-92
103. Zilberman M. 2005. Dexamethasone loaded bioresorbable films used in medical support devices: structure, degradation, crystallinity and drug release. Acta Biomater. 1(6):615-25